Properties of pramlintide and insulin upon mixing
| Autor: | Mario F. Sylvestri, Susan Strobel, Mark Fineman, Christian Weyer, Joann Data, Orville G. Kolterman, Larry Z. Shen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Amyloid medicine.medical_specialty Adolescent medicine.medical_treatment Pharmacology Placebos Subcutaneous injection Pharmacokinetics Internal medicine Diabetes mellitus medicine Humans Insulin Aged Type 1 diabetes Cross-Over Studies business.industry Health Policy Middle Aged medicine.disease Crossover study Pramlintide United States Islet Amyloid Polypeptide Drug Combinations Diabetes Mellitus Type 1 Endocrinology Area Under Curve Pharmacodynamics Female business medicine.drug |
| Zdroj: | American Journal of Health-System Pharmacy. 62:816-822 |
| ISSN: | 1535-2900 1079-2082 |
| Popis: | Purpose. The pharmacokinetics, pharmacodynamics, and safety of pramlintide and various insulin formulations in patients with type 1 diabetes mellitus (DM) when given as separate injections or mixed in the same syringe before injection were studied. Methods. In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations. Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection. Results. Blood samples were collected from a total of 51 patients. All treatments involving mixtures were comparable to separate injections with respect to the area under the concentration-versus-time curve (AUC) and the maximum concentration ( C max) of serum free insulin. There were some minor differences in the AUC and C max of pramlintide. No injection-site reactions or other unexpected adverse events were observed. Conclusion. Mixing pramlintide with short- or long-acting insulin in the same syringe before subcutaneous injection did not affect the pharmacodynamics of glucose or the pharmacokinetics of insulin or pramlintide in a clinically significant manner. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|